Jun. 11 at 5:20 PM
$INSM skyrocketed 29% after positive phase IIb data! 🚀
🌟 TPIP led to a placebo-adjusted 35% reduction in pulmonary vascular resistance for PAH patients.
📈 Year to date, INSM shares are up 32%, beating the industry’s 1% decline.
See why this breakthrough matters for
$UTHR and
$LQDA here 👉 https://www.zacks.com/commentary/2494541/insmed-stock-jumps-29-on-encouraging-pah-study-results?cid=sm-stocktwits-2-2494541-body&ADID=SYND_STOCKTWITS_TWEET_2_2494541_BODY